{
  "success": true,
  "pagesUsed": [
    3,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    23,
    34,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Window",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": "[-28, -2]",
        "relativeTo": "First Dose",
        "windowLower": -28,
        "windowUpper": -2
      },
      {
        "id": "timing_2",
        "name": "Washout Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": "[3, 14]",
        "relativeTo": "Previous Visit",
        "windowLower": 3,
        "windowUpper": 14
      },
      {
        "id": "timing_3",
        "name": "Follow-up Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Last Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_4",
        "name": "CRU Discharge Timing",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "First Dose",
        "windowLower": 0
      },
      {
        "id": "timing_5",
        "name": "Study Treatment Administration Timing",
        "type": "After",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5,
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_6",
        "name": "TE ADA Additional Follow-up Sampling",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 84,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_7",
        "name": "Hypersensitivity Reaction Follow-up Sample",
        "type": "After",
        "unit": "days",
        "instanceType": "Timing",
        "value": 30,
        "windowLower": 0,
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Admission Rescheduling Condition",
        "instanceType": "Condition",
        "description": "Condition for rescheduling admission to the CRU on Day 1 of a treatment period.",
        "text": "PG level is not 90 to 250 mg/dL on Day 1."
      },
      {
        "id": "cond_2",
        "name": "Stop Insulin Infusion Condition",
        "instanceType": "Condition",
        "description": "Condition to stop the insulin infusion used to induce hypoglycemia.",
        "text": "Bedside PG is <60 mg/dL."
      },
      {
        "id": "cond_3",
        "name": "Fasting Requirement for Lab Tests",
        "instanceType": "Condition",
        "description": "Fasting condition for lab tests during treatment periods.",
        "text": "At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures."
      },
      {
        "id": "cond_4",
        "name": "Interim Safety Review Trigger",
        "instanceType": "Condition",
        "description": "The study will pause for a safety review after a specific number of patients have completed Period 2.",
        "text": "Safety data will be reviewed after the first 6 patients (regardless of type of diabetes) are administered LY900018 in Period 2."
      },
      {
        "id": "cond_5",
        "name": "Continuation after Interim Safety Review",
        "instanceType": "Condition",
        "description": "Condition for continuing to dose patients after the interim safety review.",
        "text": "If no clinically significant safety findings for treatment or study procedure are noted, the remaining patients will be dosed."
      },
      {
        "id": "cond_6",
        "name": "TE ADA Positive at Follow-up",
        "instanceType": "Condition",
        "description": "Condition for entering the additional follow-up period for immunogenicity.",
        "text": "Patients with TE ADA at follow-up/ED will undergo additional follow-up."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Transition to Additional Follow-up",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_followup",
        "toElementId": "epoch_additional_followup",
        "text": "Patients with TE ADA at follow-up/ED will undergo additional follow-up."
      },
      {
        "id": "trans_2",
        "name": "Continuation of Inadvertently Enrolled Patient",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was inadvertently enrolled, a discussion must occur between the Lilly CP/CRP and the investigator to determine if the patient may continue in the study."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "TE ADA Follow-up Completion (Titer)",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Criteria for completing the additional follow-up for TE ADA based on titer levels."
      },
      {
        "id": "exit_2",
        "name": "TE ADA Follow-up Completion (Time Limit)",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Maximum duration for the additional follow-up for TE ADA."
      },
      {
        "id": "exit_3",
        "name": "Discontinuation due to Other Study Participation",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient is enrolled in another incompatible clinical study."
      },
      {
        "id": "exit_4",
        "name": "Discontinuation by Investigator Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The investigator decides the patient should be discontinued from the study for any reason."
      },
      {
        "id": "exit_5",
        "name": "Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The patient, or legal representative, requests to be withdrawn from the study."
      },
      {
        "id": "exit_6",
        "name": "Study Termination for Safety",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The entire study may be stopped for patient safety reasons after the interim safety review."
      },
      {
        "id": "exit_7",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient repeatedly fails to return for scheduled visits and cannot be contacted."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Interim Safety Review Decision",
        "timepointId": "After first 6 patients complete Period 2 Day 1",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to continue dosing remaining patients or stop the study based on safety data from the first 6 patients administered LY900018 in Period 2.",
        "conditionIds": [
          "cond_4",
          "cond_5"
        ]
      },
      {
        "id": "dec_2",
        "name": "Transition to Additional Follow-up Decision",
        "timepointId": "Follow-up/ED Visit",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to move a patient into an additional follow-up period if they are TE ADA positive at the Follow-up/ED visit.",
        "conditionIds": [
          "cond_6"
        ]
      },
      {
        "id": "dec_3",
        "name": "Admission Rescheduling Decision",
        "timepointId": "Period 1 Day 1 and Period 2 Day 1",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to reschedule admission if a patient's plasma glucose level is outside the 90-250 mg/dL range on the day of admission.",
        "conditionIds": [
          "cond_1"
        ]
      }
    ],
    "summary": {
      "timingCount": 7,
      "conditionCount": 6,
      "transitionRuleCount": 2,
      "exitCount": 7
    }
  }
}